Anavex Life Sciences (AVXL) Depreciation & Amortization (CF) (2010 - 2016)
Anavex Life Sciences recorded quarterly Depreciation & Amortization (CF) of $506.0 in Q3 2016, up 103.21% quarter-over-quarter from $249.0 in Q2 2016, and up 103.21% year-over-year from $249.0 in Q4 2015.
Anavex Life Sciences' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $506.0 for Q3 2016.
- In Q3 2016, Depreciation & Amortization (CF) rose 103.21% year-over-year to $506.0; the TTM figure through Jun 2017 stood at $506.0 (down 49.15% YoY), while the FY2016 annual figure was $1252.0, up 25.83% from the prior year.
- Depreciation & Amortization (CF) came in at $506.0 for Q3 2016 at Anavex Life Sciences, up from $249.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $506.0 in Q3 2016 to a low of $111.0 in Q1 2013.
- A 5-year average of $293.24 and a median of $249.0 in 2014 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) sank 76.13% in 2013 and surged 103.21% in 2016, its largest moves.
- Anavex Life Sciences' Depreciation & Amortization (CF) stood at $465.0 in 2012, then slumped by 58.71% to $192.0 in 2013, then increased by 29.69% to $249.0 in 2014, then changed by 0.0% to $249.0 in 2015, then soared by 103.21% to $506.0 in 2016.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $506.0, $249.0, and $248.0 for Q3 2016, Q2 2016, and Q1 2016 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 506.00 |
| Sep 30, 2016 | 506.00 |
| Jun 30, 2016 | 249.00 |
| Jun 30, 2016 | 249.00 |
| Mar 31, 2016 | 248.00 |
| Mar 31, 2016 | 248.00 |
| Dec 31, 2015 | 249.00 |
| Dec 31, 2015 | 249.00 |
| Sep 30, 2015 | 249.00 |
| Sep 30, 2015 | 249.00 |
| Jun 30, 2015 | 248.00 |
| Jun 30, 2015 | 248.00 |
| Mar 31, 2015 | 249.00 |
| Mar 31, 2015 | 249.00 |
| Dec 31, 2014 | 249.00 |
| Dec 31, 2014 | 249.00 |
| Sep 30, 2014 | 192.00 |
| Sep 30, 2014 | 192.00 |
| Jun 30, 2014 | 192.00 |
| Jun 30, 2014 | 192.00 |
| Mar 31, 2014 | 192.00 |
| Mar 31, 2014 | 192.00 |
| Dec 31, 2013 | 192.00 |
| Dec 31, 2013 | 192.00 |
| Mar 31, 2013 | 111.00 |
| Mar 31, 2013 | 111.00 |
| Dec 31, 2012 | 465.00 |
| Dec 31, 2012 | 465.00 |
| Sep 30, 2012 | 464.00 |
| Sep 30, 2012 | 464.00 |
| Jun 30, 2012 | 465.00 |
| Jun 30, 2012 | 465.00 |
| Mar 31, 2012 | 465.00 |
| Mar 31, 2012 | 465.00 |
| Dec 31, 2011 | 464.00 |
| Dec 31, 2011 | 464.00 |
| Sep 30, 2011 | 382.00 |
| Sep 30, 2011 | 382.00 |
| Jun 30, 2011 | 377.00 |
| Jun 30, 2011 | 377.00 |
| Mar 31, 2011 | 407.00 |
| Mar 31, 2011 | 407.00 |
| Dec 31, 2010 | 491.00 |
| Dec 31, 2010 | 491.00 |
| Sep 30, 2010 | 340.00 |
| Sep 30, 2010 | 340.00 |